Literature DB >> 10927166

Iron oxide-enhanced MR lymphography: initial experience.

M F Bellin1, C Beigelman, S Precetti-Morel.   

Abstract

The detection of nodal metastases is of utmost importance in oncologic imaging. Ultrasmall superparamagnetic iron oxide particles (USPIO) are novel contrast agents specifically developed for MR lymphography. After intravenous administration, they are taken up by the macrophages of the lymph nodes, where they accumulate. They reduce the signal intensity (SI) of normally functioning nodes on postcontrast T2-and T2*-weighted images through the magnetic susceptibility effects on iron oxide. Metastatic nodes, in which macrophages are replaced by tumor cells, show no significant change in SI on postcontrast T2-and T2*-weighted images. Early clinical experience suggests that USPIO-enhanced MR lymphography improves the sensitivity and specificity for the detection of nodal metastases. It also suggests that micrometastases could be detected in normal-sized nodes. This article reviews the physiochemical properties of USPIO contrast agents, their enhancement patterns, and early clinical experience.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10927166     DOI: 10.1016/s0720-048x(00)00204-7

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  14 in total

Review 1.  Preclinical lymphatic imaging.

Authors:  Fan Zhang; Gang Niu; Guangming Lu; Xiaoyuan Chen
Journal:  Mol Imaging Biol       Date:  2011-08       Impact factor: 3.488

2.  Hybrid 99mTc-magnetite tracer for dual modality sentinel lymph node mapping.

Authors:  Aidan Cousins; Chris Tsopelas; George Balalis; Sarah K Thompson; Dylan Bartholomeusz; A Bruce Wedding; Benjamin Thierry
Journal:  J Mater Sci Mater Med       Date:  2018-05-29       Impact factor: 3.896

3.  MR imaging of rectal cancer before and after chemoradiation therapy.

Authors:  R Del Vescovo; L E Trodella; I Sansoni; R L Cazzato; S Battisti; F Giurazza; S Ramella; F Cellini; R F Grasso; L Trodella; B Beomonte Zobel
Journal:  Radiol Med       Date:  2012-03-20       Impact factor: 3.469

Review 4.  Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases.

Authors:  Gregory A Joice; Steven P Rowe; Michael A Gorin; Phillip M Pierorazio
Journal:  Curr Urol Rep       Date:  2018-11-09       Impact factor: 3.092

5.  Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of cancer.

Authors:  Sophie Laurent; Morteza Mahmoudi
Journal:  Int J Mol Epidemiol Genet       Date:  2011-11-25

6.  Breast imaging. Preoperative breast cancer staging: comparison of USPIO-enhanced MR imaging and 18F-fluorodeoxyglucose (FDC) positron emission tomography (PET) imaging for axillary lymph node staging--initial findings.

Authors:  Tadeusz W Stadnik; Hendrik Everaert; Smitha Makkat; Robert Sacré; Jan Lamote; Claire Bourgain
Journal:  Eur Radiol       Date:  2006-05-03       Impact factor: 5.315

Review 7.  Lymphotropic nanoparticle-enhanced MRI in prostate cancer: value and therapeutic potential.

Authors:  Ansje S Fortuin; Robert Jan Smeenk; Hanneke J M Meijer; Alfred J Witjes; Jelle O Barentsz
Journal:  Curr Urol Rep       Date:  2014-03       Impact factor: 3.092

8.  USPIO-enhanced MR imaging of macrophage infiltration in native and transplanted kidneys: initial results in humans.

Authors:  Olivier Hauger; Nicolas Grenier; Colette Deminère; Catherine Lasseur; Yahsou Delmas; Pierre Merville; Christian Combe
Journal:  Eur Radiol       Date:  2007-05-22       Impact factor: 5.315

9.  USPIO-enhanced MRI for preoperative staging of gynecological pelvic tumors: preliminary results.

Authors:  Thomas M Keller; Sven C A Michel; Johannes Fröhlich; Daniel Fink; Rosmarie Caduff; Borut Marincek; Rahel A Kubik-Huch
Journal:  Eur Radiol       Date:  2004-02-26       Impact factor: 5.315

10.  Dextran and polymer polyethylene glycol (PEG) coating reduce both 5 and 30 nm iron oxide nanoparticle cytotoxicity in 2D and 3D cell culture.

Authors:  Miao Yu; Shaohui Huang; Kevin Jun Yu; Alisa Morss Clyne
Journal:  Int J Mol Sci       Date:  2012-05-09       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.